BOARD OF DIRECTORS
David Bonita, M.D.
David is a Partner on the private equity team. Prior to joining OrbiMed, Dr. Bonita worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS.
He has also published scientific articles in peer reviewed journals based on signal transduction research performed at the Harvard Medical School. Dr. Bonita received his A.B. degree magna cum laude in Biological Sciences from Harvard University and his joint M.D./M.B.A. from Columbia University where he was elected to the Alpha Omega Alpha Medical Honor Society and Beta Gamma Sigma Business Honor Society.
Jerel Davis, PhD
Managing Director, Versant Ventures
Jerel is a Managing Director based at Versant Ventures. Since joining Versant in 2011, he has played a critical role in launching and investing in a number of Versant’s portfolio companies including Quanticel Pharmaceuticals, Crispr Therapeutics, Blueline Bioscience, Northern Biologics and several of the Inception Sciences discovery start-ups.
He has also led Versant’s execution of build-to-buy structured acquisitions with Celgene, Roche and Bayer. Over the last few years, Jerel has focused on establishing Versant’s presence in Canada, including the launch of new companies in Vancouver, Toronto and Montreal. Prior to joining Versant, Jerel was Associate Principal at McKinsey and Company where he advised healthcare corporations in pharmaceuticals, biotechnology, medical device and molecular diagnostics. He has worked in a number of healthcare markets globally including the US, Europe, China, Russia and India. Jerel was a post doctoral researcher at Stanford University until 2005 and in research at Amgen from 1999-2000.
Managing Director, MPM Capital
Todd is a Managing Director at MPM Capital. He focuses on biotech investments, and in addition to serving on Repare’s board, he serves on a number of MPM portfolio company boards, including Switch Bio, Chiasma (CHMA), ClinicalInk, Iconic, Rhythm, Semma and Tetherex.
Todd also manages MPM’s strategic investment relationship with Novartis (NVS), which MPM believes has been one of the industry’s longest standing and most prolific collaborations between venture capital investors and pharma, having committed $200 million to over a dozen companies in the biotech and healthcare IT space under a variety of creative joint equity/strategic deal structures.
Prior to MPM, Todd’s career in the life science industry included Business Development at Genentech (acquired by Roche) and management consulting with Arthur D. Little. He holds a B.S. in Chemistry from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
CEO, CRISPR Therapeutics
Sam has served as CEO of CRISPR Therapeutics since 2017. He has significant expertise in strategy and operations in biotechnology and a wide range of related cutting-edge therapeutic technologies. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer, and then served as President and Chief Business Officer. Prior to joining CRISPR, Sam was a Partner at McKinsey & Company, where he had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, he co-led the biotech practice, where he focused on topics ranging from strategy to operations and led initiatives in areas such as personalized medicine and immunotherapy. Sam also serves as the Chairman of the Board of Directors of Casebia Therapeutics, a joint subsidiary formed by CRISPR Therapeutics and Bayer.
He received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. While at the University of Washington, he conducted research in the delivery of biological drugs and in the field of molecular diagnostics. He has authored several publications in leading scientific and business journals.
Briggs W. Morrison, MD
CEO, Syndax Pharmaceuticals
Briggs is the CEO of Syndax Pharmaceuticals (NASDAQ:SNDX), a biopharmaceutical company focused on developing an innovative pipeline of combination therapies in multiple cancer indications. Dr. Morrison also currently serves as a managing director of MPM Capital, a healthcare-focused venture capital firm.
Dr. Morrison previously served as EVP, Global Medicines Development and Chief Medical Officer at AstraZeneca plc, leading the company’s global, late-stage development organization and serving as a member of the AstraZeneca senior executive team. He previously held a number of positions at Pfizer Inc., that culminated in his appointment as Head, Medical Affairs, Safety and Regulatory Affairs for Pfizer’s human health business, and also served in roles of increasing responsibility within Merck & Co., Inc., including the role of VP, Clinical Sciences, Oncology, responsible for clinical development of all novel anti-cancer drugs. Dr. Morrison was chairman of the board of TransCelerate BioPharma Inc., an industry-funded company charged with improving aspects of clinical trials, a member of the executive committee of the Clinical Trials Transformation Initiative (CTTI) sponsored by FDA, and is on the board of ACRES (Alliance for Clinical Research Excellence and Safety) and Oncorus, Inc. Dr. Morrison received a B.S. in biology from Georgetown University and an M.D. from the University of Connecticut. He completed his training in Internal Medicine at the Massachusetts General Hospital, and training in Medical Oncology at the Dana Farber Cancer Institute.
Managing Partner, Cowen Healthcare Investments
Kevin is Managing Partner, Cowen Healthcare Investments. Previously, Mr. Raidy was Cowen’s Head of Investment Banking and prior to that he served as co-head of Cowen’s equity capital markets group, which is responsible for the origination and execution of all equity capital-raising transactions. Before that, he was a managing director at Cowen Investment Management (formerly known as Ramius LLC), where he was portfolio manager for direct investments and convertible bonds. Mr. Raidy also was the founder of H4 Capital Management LLC.
His sell-side experience includes ten years at Shipley Raidy Capital Partners LP, a boutique investment banking firm that he co-founded, where he was responsible for sourcing, evaluating, and structuring numerous debt and equity financings and also performed M&A advisory services.
Prior to founding Shipley Raidy, Mr. Raidy was an associate at Philadelphia First Group. He started his career at Cantor Fitzgerald before moving to Merrill Lynch as an analyst in the municipal finance group.
Mr. Raidy holds a BS in economics with a concentration in finance from the Wharton School of the University of Pennsylvania.
Carol is a seasoned financial professional with more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development. She most recently served as Vice Chair, Equity Capital Markets at Wells Fargo Securities.
Prior to Wells Fargo, Ms. Schafer served as Vice President of Finance and Business Development at Lexicon Pharmaceuticals. Earlier in her career, she was a Managing Director and equity capital markets sector head at J.P. Morgan. She currently sits on the Board of Directors of Idera Pharmaceuticals, Inc. (Nasdaq: IDRA). Ms. Schafer received a B.A. from Boston College and an M.B.A from New York University.
Lloyd M. Segal
President & CEO, Repare Therapeutics
In addition to his role as Repare’s President & CEO, Lloyd is an Entrepreneur-in-residence at Versant Ventures. From 2010-2016 he was a Managing Partner at Persistence Capital Partners, a leading healthcare private equity investor. Lloyd held CEO roles at Caprion Pharmaceticals, Advanced Bioconcept and Thallion Pharmaceuticals, and has served as a director of several public and private corporations in the U.S. and Canada.
In 2013, Lloyd was honored by the Financial Times as Outstanding Corporate Director of the Year. He currently acts as Chairman of LMC Diabetes & Endocrinology, North America’s largest community endocrinology and diabetes practice, as a member of the Board of GBC American Fund, a US growth-focused mutual fund, and was Board Chairman of MedReleaf Inc. (TSX:LEAF), Canada’s leading medical cannabis provider until its sale to Aurora Cannabis (TSX:ACB) for $3.2 billion in July, 2018.
Lloyd holds a BA from Brandeis University and an MBA from Harvard Business School.